Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 2 Incidence of adverse events of the study population receiving Azvudine or Paxlovid treatment

From: Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases

Adverse events (N, %)

Available dataa

Grade 1b

Grade 2b

Grade ≥ 3b

Azvudine

(674)

Paxlovid (364)

Azvudine

n (%)

Paxlovid

n (%)

P value

Azvudine

n (%)

Paxlovid

n (%)

P value

Azvudine

n (%)

Paxlovid

n (%)

P value

ALT increased

423

250

103 (24%)

86 (34%)

0.005

22 (5.2%)

20 (8.0%)

0.15

18 (4.3%)

13 (5.2%)

0.6

AST increased

433

254

78 (18%)

62 (24%)

0.045

20 (4.6%)

10 (3.9%)

0.7

23 (5.3%)

12 (4.7%)

0.7

ALP increased

421

250

39 (9.3%)

24 (9.6%)

0.9

1 (0.2%)

5 (2.0%)

0.029

0 (0%)

1 (0.4%)

0.4

GGT increased

339

242

50 (15%)

48 (20%)

0.11

15 (4.4%)

13 (5.4%)

0.6

3 (0.9%)

7 (2.9%)

0.10

CREA increased

433

247

20 (4.6%)

13 (5.3%)

0.7

24 (5.5%)

12 (4.9%)

0.7

14 (3.2%)

5 (2.0%)

0.4

Hyperuricemia

377

243

42 (11%)

11 (4.5%)

0.004

0

0

NA

0

0

NA

Hypokalemia

467

279

55 (12%)

43 (15%)

0.2

55 (12%)

43 (15%)

0.2

56 (12%)

29 (10%)

0.5

Hyperkalemia

467

279

24 (5.1%)

11 (3.9%)

0.5

23 (4.9%)

11 (3.9%)

0.5

9 (1.9%)

1 (0.4%)

0.10

Hypoglycemia

149

13

38 (26%)

4 (31%)

0.7

0

0

NA

0

0

NA

Hypercholesteremia

107

43

6 (5.6%)

7 (16%)

0.052

1 (0.9%)

0 (0%)

>0.9

0

0

NA

Hypertriglyceridemia

90

40

14 (16%)

10 (25%)

0.2

1 (1.1%)

1 (2.5%)

0.5

1 (1.1%)

0 (0%)

>0.9

Lymphocyte count decreased

570

296

24 (4.2%)

14 (4.7%)

0.7

56 (9.8%)

26 (8.8%)

0.6

153 (27%)

94 (32%)

0.13

Lymphocyte count increased

570

296

6 (1.1%)

4 (1.4%)

0.7

9 (1.6%)

3 (1.0%)

0.8

0 (0%)

2 (0.7%)

0.12

Neutrophil count increased

377

248

6 (1.6%)

4 (1.6%)

>0.9

7 (1.9%)

3 (1.2%)

0.7

7 (1.9%)

3 (1.2%)

0.7

Platelets-count decreased

437

255

26 (5.9%)

18 (7.1%)

0.6

13 (3.0%)

13 (5.1%)

0.2

31 (7.1%)

22 (8.6%)

0.5

Hemoglobin decreased

389

252

66 (17%)

41 (16%)

0.8

41 (11%)

26 (10%)

>0.9

51 (13%)

34 (13%)

0.9

  1. ALT alanine aminotransferase; AST aspartate aminotransferase; ALP alkaline phosphatase; GGT gamma-glutamyl transpeptidase; CREA creatinine
  2. aNumber of patients who completed the follow-up of data collection for this clinical parameter
  3. bThe grades of adverse events were defined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0
Back to article page

Virology Journal

ISSN: 1743-422X